AR128669A1 - INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS - Google Patents
INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOSInfo
- Publication number
- AR128669A1 AR128669A1 ARP230100509A ARP230100509A AR128669A1 AR 128669 A1 AR128669 A1 AR 128669A1 AR P230100509 A ARP230100509 A AR P230100509A AR P230100509 A ARP230100509 A AR P230100509A AR 128669 A1 AR128669 A1 AR 128669A1
- Authority
- AR
- Argentina
- Prior art keywords
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- aryl
- nrcrd
- Prior art date
Links
- 108010062677 Diacylglycerol Kinase Proteins 0.000 title abstract 4
- 102000011107 Diacylglycerol Kinase Human genes 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 21
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 19
- 125000001072 heteroaryl group Chemical group 0.000 abstract 18
- 125000003118 aryl group Chemical group 0.000 abstract 16
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 10
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 10
- -1 C1-C6aminoalkyl Chemical group 0.000 abstract 8
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 7
- 125000003342 alkenyl group Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000304 alkynyl group Chemical group 0.000 abstract 7
- 125000004429 atom Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 101150050688 DGKA gene Proteins 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 101710096001 Diacylglycerol kinase A Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022078653 | 2022-03-01 | ||
| CN2022091497 | 2022-05-07 | ||
| CN2022127020 | 2022-10-24 | ||
| CN2023071857 | 2023-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128669A1 true AR128669A1 (es) | 2024-06-05 |
Family
ID=87883011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100509A AR128669A1 (es) | 2022-03-01 | 2023-03-01 | INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240051958A1 (enExample) |
| EP (1) | EP4486741A4 (enExample) |
| JP (1) | JP2025508971A (enExample) |
| KR (1) | KR20240156394A (enExample) |
| CN (1) | CN118871438A (enExample) |
| AR (1) | AR128669A1 (enExample) |
| AU (1) | AU2023227010A1 (enExample) |
| CA (1) | CA3244501A1 (enExample) |
| IL (1) | IL315015A (enExample) |
| MX (1) | MX2024010648A (enExample) |
| TW (1) | TW202342477A (enExample) |
| WO (1) | WO2023165504A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315015A (en) | 2022-03-01 | 2024-10-01 | Insilico Medicine Ip Ltd | Diacylglycerol kinase (DGK) alpha inhibitors and their uses |
| TW202436351A (zh) | 2023-02-06 | 2024-09-16 | 德商拜耳廠股份有限公司 | Ccr8抗體及dgk抑制劑之組合 |
| CN122094689A (zh) * | 2023-09-04 | 2026-05-26 | 英矽智能科技知识产权有限公司 | 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100477070B1 (ko) | 1994-03-25 | 2006-04-21 | 이소테크니카 인코포레이티드 | 중수소화작용에의한의약품의효능강화법 |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| AU2004220176A1 (en) | 2003-03-14 | 2004-09-23 | Astrazeneca Ab | Novel fused triazolones and the uses thereof |
| GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| WO2011075747A1 (en) | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Therapeutic compounds |
| US10376504B2 (en) * | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
| CN111406050B (zh) * | 2018-01-17 | 2023-02-03 | 厦门宝太生物科技股份有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其用途 |
| SG11202012973RA (en) | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| MA56444A (fr) | 2019-07-04 | 2022-05-11 | Lead Pharma Holding Bv | MODULATEURS DU RÉCEPTEUR ALPHA DES OESTROGÈNES (ERRalpha) |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| HRP20240237T1 (hr) | 2019-10-18 | 2024-05-10 | Lead Pharma Holding B.V. | Modulatori receptora alfa (err-alfa) povezanih s estrogenom |
| US12478621B2 (en) * | 2019-11-28 | 2025-11-25 | Deutsches Krebsforschungszentrum | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| WO2021105115A1 (en) | 2019-11-28 | 2021-06-03 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| EP4065584A1 (en) | 2019-11-28 | 2022-10-05 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| WO2021127554A1 (en) | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
| CA3162979A1 (en) | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| MX2022007369A (es) | 2019-12-23 | 2022-07-12 | Bristol Myers Squibb Co | Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. |
| IL294148A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinazolinyl compounds are useful as t-cell activators |
| JP7677976B2 (ja) * | 2019-12-23 | 2025-05-15 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物 |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| AU2021400725A1 (en) | 2020-12-16 | 2023-08-03 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CA3228862A1 (en) | 2021-08-03 | 2023-02-09 | Beigene, Ltd. | Pyrazolopyridinone compounds |
| WO2023165528A1 (en) | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| EP4486745A4 (en) | 2022-03-01 | 2026-03-11 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| WO2023165525A1 (en) | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| IL315015A (en) | 2022-03-01 | 2024-10-01 | Insilico Medicine Ip Ltd | Diacylglycerol kinase (DGK) alpha inhibitors and their uses |
| JP2025510945A (ja) | 2022-03-31 | 2025-04-15 | インベンティスバイオ カンパニー リミテッド | キナーゼ阻害剤、その製造方法および用途 |
| WO2023184327A1 (en) | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
-
2023
- 2023-03-01 IL IL315015A patent/IL315015A/en unknown
- 2023-03-01 JP JP2024552216A patent/JP2025508971A/ja active Pending
- 2023-03-01 AU AU2023227010A patent/AU2023227010A1/en active Pending
- 2023-03-01 AR ARP230100509A patent/AR128669A1/es unknown
- 2023-03-01 EP EP23762903.5A patent/EP4486741A4/en active Pending
- 2023-03-01 TW TW112107272A patent/TW202342477A/zh unknown
- 2023-03-01 CA CA3244501A patent/CA3244501A1/en active Pending
- 2023-03-01 WO PCT/CN2023/078948 patent/WO2023165504A1/en not_active Ceased
- 2023-03-01 CN CN202380024550.4A patent/CN118871438A/zh active Pending
- 2023-03-01 KR KR1020247032094A patent/KR20240156394A/ko active Pending
- 2023-10-13 US US18/486,374 patent/US20240051958A1/en active Pending
- 2023-11-13 US US18/507,595 patent/US12077538B2/en active Active
-
2024
- 2024-08-29 MX MX2024010648A patent/MX2024010648A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486741A1 (en) | 2025-01-08 |
| IL315015A (en) | 2024-10-01 |
| WO2023165504A1 (en) | 2023-09-07 |
| KR20240156394A (ko) | 2024-10-29 |
| EP4486741A4 (en) | 2026-04-08 |
| US12077538B2 (en) | 2024-09-03 |
| CA3244501A1 (en) | 2023-09-07 |
| US20240051958A1 (en) | 2024-02-15 |
| TW202342477A (zh) | 2023-11-01 |
| AU2023227010A1 (en) | 2024-09-12 |
| JP2025508971A (ja) | 2025-04-10 |
| US20240116935A1 (en) | 2024-04-11 |
| CN118871438A (zh) | 2024-10-29 |
| MX2024010648A (es) | 2024-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128668A1 (es) | INHIBIDORES DE DIACILGLICEROL CINASA (DGK) a Y USOS DE LOS MISMOS | |
| AR128383A1 (es) | Inhibidores de ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos | |
| AR127500A1 (es) | Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos | |
| PE20251071A1 (es) | Inhibidores de kras | |
| PE20250259A1 (es) | Compuestos de pirido[4,3-d] pirimidina | |
| AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
| AR068109A1 (es) | Derivados tetraciclicos de indol y una composicion farmaceutica | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR114044A1 (es) | Composiciones y métodos para el tratamiento de trastornos en el sistema nervioso central | |
| AR120652A1 (es) | Antagonistas de sstr5 | |
| AR068107A1 (es) | Derivados indolicos 2,3 sustituidos y una composicion farmaceutica | |
| AR089175A1 (es) | Inhibidores de pak para el tratamiento de trastornos de proliferacion celular | |
| AR115092A1 (es) | Inhibidores de magl | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| AR121715A1 (es) | Pirrolopirimidinaminas como inhibidores del sistema del complemento | |
| AR064429A1 (es) | Derivados indolicos con anillo unidos en las posiciones 4,5, composiciones farmaceuticas que los contienen y usos de los mismos en la prevencion y/o tratamiento de infecciones virales. | |
| AR092536A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| AR117472A1 (es) | Inhibidores de tienopiridina de ripk2 | |
| AR092306A1 (es) | Antibacterianos de fenicol | |
| AR128418A1 (es) | Inhibidores de la proteína tirosina fosfatasa y usos de estos | |
| DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| AR087470A1 (es) | Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen | |
| CL2021003139A1 (es) | Compuestos tricíclicos |